Undoubtedly, the technology industry has tested the meaning of this concept. The conservative sentiment surrounding the stock market, have made investors caution of the long-term risks in biotechnology, even though the basic investment thesis is as sound today, as it was a year ago. Biotechs don't have inventory corrections and or most biotechs don't have earnings with potential shortfalls as like the tech stocks, therefore in the current economic environment biotech stocks prices appeared to have stabilized. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company.
Additional information is available upon request.
Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments.